Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma

被引:33
作者
Gonzalez-Martinez, Silvia [1 ]
Perez-Mies, Belen [2 ,3 ,4 ,5 ,6 ]
Carretero-Barrio, Irene [2 ]
Luisa Palacios-Berraquero, Maria [7 ]
Perez-Garcia, Jose [8 ]
Cortes, Javier [4 ,8 ,9 ,10 ,11 ,12 ]
Palacios, Jose [2 ,3 ,4 ,5 ,6 ]
机构
[1] Hosp Univ Raman y Cajal, Madrid 28034, Spain
[2] Hosp Univ Raman y Cajal, Pathol Dept, Madrid 28034, Spain
[3] Inst Raman y Cajal Hlth Res IRYCIS, Madrid 28034, Spain
[4] Inst Salud Carlos III, CIBER ONC, Madrid 28029, Spain
[5] Univ Alcala, Fac Med, Madrid 28801, Spain
[6] Hosp Univ Raman y Cajal, Breast Pathol Unit, Madrid 28801, Spain
[7] Clin Univ Navarra, Hematol & Hemotherapy Dept, Pamplona 31008, Spain
[8] Hosp Quiron, Quironsalud Grp, IOB Inst Oncol, Barcelona 08023, Spain
[9] IOB Inst Oncol, Quironsalud Grp, Madrid 28006, Spain
[10] Med Sci Innovat Res, Barcelona 08018, Spain
[11] Med Sci Innovat Res, Ridgewood, NJ 07450 USA
[12] Vall dHebron Inst Oncol, Barcelona 08035, Spain
关键词
MBC; metaplastic breast carcinoma; molecular alterations; prognosis; treatment; TO-MESENCHYMAL TRANSITION; STEM-CELL; REVEALS FREQUENT; WORSE PROGNOSIS; CANCER; EXPRESSION; MARKERS; IDENTIFICATION; HETEROGENEITY; CHEMOTHERAPY;
D O I
10.3390/cancers12071832
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent invasive carcinomas that display differentiation of the neoplastic epithelium towards squamous cells and/or mesenchymal-type elements. Most MBC have a triple negative phenotype and poor prognosis. Thus, MBC have worse survival rates than other invasive breast carcinomas, including other triple negative breast carcinomas (TNBC). In this study, we reviewed the molecular features of MBC, pointing out the differences among subtypes. The most frequently mutated genes in MBC wereTP53andPIK3CA. Additionally, mutations in the other genes of the PI3K/AKT pathway indicated its importance in the pathogenesis of MBC. Regarding copy number variations (CNVs),MYCwas the most frequently amplified gene, and the most frequent gene loss affected theCDKN2A/CDKN2Blocus. Furthermore, the pattern of mutations and CNVs of MBC differed from those reported in other TNBC. However, the molecular profile of MBC was not homogeneous among histological subtypes, being the alterations in the PI3K pathway most frequent in spindle cell carcinomas. Transcriptomic studies have demonstrated an epithelial to mesenchymal program activation and the enrichment of stemness genes in most MBC. In addition, current studies are attempting to define the immune microenvironment of these tumors. In conclusion, due to specific molecular features, MBC have a different clinical behavior from other types of TNBC, being more resistant to standard chemotherapy. For this reason, new therapeutic approaches based on tumor molecular characteristics are needed to treat MBC.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 84 条
[1]   Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors [J].
Abraham Barquet-Munoz, Salim ;
Patricia Villarreal-Colin, Silvia ;
Alonso Herrera-Montalvo, Luis ;
Soto-Reyes, Ernesto ;
Perez-Plasencia, Carlos ;
Coronel-Martinez, Jaime ;
Perez-Montiel, Delia ;
Vazquez-Romo, Rafael ;
Cantu de Leon, David .
BMC CANCER, 2015, 15
[2]   Dramatic response of metaplastic breast cancer to chemo-immunotherapy [J].
Adams, Sylvia .
NPJ BREAST CANCER, 2017, 3
[3]   Mutation and immune profiling of metaplastic breast cancer: Correlation with survival [J].
Afkhami, Michelle ;
Schmolze, Daniel ;
Yost, Susan E. ;
Frankel, Paul H. ;
Dagis, Andrew ;
Amanam, Idoroenyi U. ;
Telatar, Milhan ;
Nguyen, Kim ;
Yu, Kim Wai ;
Thehang Luu ;
Pillai, Raju ;
Aoun, Patricia A. ;
Mortimer, Joanne ;
Yuan, Yuan .
PLOS ONE, 2019, 14 (11)
[4]   Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination [J].
Al Sayed, Adher D. ;
Elshenawy, Mahmoud A. ;
Tulbah, Asma ;
Al-Tweigeri, Taher ;
Ghebeh, Hazem .
AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 :1630-1635
[5]   Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy [J].
Al-Hilli, Zahraa ;
Choong, Grace ;
Keeney, Michael G. ;
Visscher, Daniel W. ;
Ingle, James N. ;
Goetz, Matthew P. ;
Jakub, James W. .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 176 (03) :709-716
[6]   MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes [J].
Angeles Castilla, Maria ;
Diaz-Martin, Juan ;
Sarrio, David ;
Romero-Perez, Laura ;
Angeles Lopez-Garcia, Maria ;
Vieites, Begona ;
Biscuola, Michele ;
Ramiro-Fuentes, Susana ;
Isacke, Clare M. ;
Palacios, Jose .
PLOS ONE, 2012, 7 (10)
[7]   Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment [J].
Aydiner, Adnan ;
Sen, Fatma ;
Tambas, Makbule ;
Ciftci, Rumeysa ;
Eralp, Yesim ;
Saip, Pinar ;
Karanlik, Hasan ;
Fayda, Merdan ;
Kucucuk, Seden ;
Onder, Semen ;
Yavuz, Ekrem ;
Muslumanoglu, Mahmut ;
Igci, Abdullah .
MEDICINE, 2015, 94 (52)
[8]   The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients [J].
Bae, Soo Youn ;
Lee, Se Kyung ;
Koo, Min Young ;
Hur, Sung Mo ;
Choi, Min-Young ;
Cho, Dong Hui ;
Kim, Sangmin ;
Choe, Jun-Ho ;
Lee, Jeong Eon ;
Kim, Jung-Han ;
Kim, Jee Soo ;
Nam, Seok Jin ;
Yang, Jung-Hyun .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (02) :471-478
[9]   Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression [J].
Barnes, PJ ;
Boutilier, R ;
Chiasson, D ;
Rayson, D .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 91 (02) :173-178
[10]   Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer [J].
Basho, Reva K. ;
Yam, Clinton ;
Gilcrease, Michael ;
Murthy, Rashmi K. ;
Helgason, Thorunn ;
Karp, Daniel D. ;
Meric-Bernstam, Funda ;
Hess, Kenneth R. ;
Valero, Vicente ;
Albarracin, Constance ;
Litton, Jennifer K. ;
Chavez-MacGregor, Mariana ;
Hong, David ;
Kurzrock, Razelle ;
Hortobagyi, Gabriel N. ;
Janku, Filip ;
Moulder, Stacy L. .
ONCOLOGIST, 2018, 23 (11) :1300-1309